Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Public ClinicalTrials.gov record NCT01772004. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .
Study identification
- NCT ID
- NCT01772004
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 1,756 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2013 (Actual)
- Primary completion
- Dec 16, 2019 (Actual)
- Completion
- Dec 16, 2019 (Actual)
- Last update posted
- Dec 20, 2021
2013 – 2019
United States locations
- U.S. sites
- 53
- U.S. states
- 23
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer Treatment Centers of America - Western Regional Medical Center | Goodyear | Arizona | 85338 | — |
| Scottsdale Healthcare Corporation | Scottsdale | Arizona | 85258-4550 | — |
| Pinnacle Oncology Hematology | Scottsdale | Arizona | 85258 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Pacific Cancer Medical Center, Inc. | Anaheim | California | 92801 | — |
| California Cancer Associates for Research & Excellence, Inc | Encinitas | California | 92024 | — |
| Healing Hands Oncology and Medical Care | Inglewood | California | 90305 | — |
| Scripps Health dba Scripps Clinical Research Services | La Jolla | California | 92037 | — |
| The Angeles Clinic and Research Institute - West LA | Los Angeles | California | 90025 | — |
| Cedars-Sinai Medical Center - Oncology | Los Angeles | California | 90048 | — |
| University of California Davis Health System | Sacramento | California | 95817 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Georgetown University Medical Center- Research Parent | Washington D.C. | District of Columbia | 20057 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Hematology - Oncology Associates of Treasure Coast - Hematology-Oncology Associates of Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Northeast Georgia Cancer Care, LLC | Athens | Georgia | 30607 | — |
| Peachtree Hematology-Oncology Consultants, PC | Atlanta | Georgia | 30318 | — |
| Augusta University - formerly Georgia Regents University | Augusta | Georgia | 30912 | — |
| Northwest Georgia Oncology Centers PC | Marietta | Georgia | 30060 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Horizon Oncology Research, INC | Lafayette | Indiana | 47905 | — |
| The Johns Hopkins Hospital | Baltimore | Maryland | 21287-7049 | — |
| RCCA MD LLC - Bethesda | Bethesda | Maryland | 20817 | — |
| National Cancer Institute | Bethesda | Maryland | 20892 | — |
| Maryland Oncology Hematology, P.A. | Rockville | Maryland | 20850 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Henry Ford Medical Center | Detroit | Michigan | 48202 | — |
| Michigan State University | Lansing | Michigan | 48910 | — |
| Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Kansas City Research Institute, LLC - Phase I Unit | Kansas City | Missouri | 64131 | — |
| Washington University in St. Louis | St Louis | Missouri | 63110 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Columbia University College of Phys & Surgeons | New York | New York | 10032 | — |
| Montefiore Medical Center PRIME | The Bronx | New York | 10461 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center | Huntersville | North Carolina | 28078 | — |
| UC Health Clinical Trials Office | Cincinnati | Ohio | 45267-0502 | — |
| University Hospitals Case Medical Center - Case Comprehensive Cancer Center | Cleveland | Ohio | 44106 | — |
| OSU - James Comprehensive Cancer Center - Division of Hematology | Columbus | Ohio | 43210-1228 | — |
| Mid Ohio Oncology Hematology, DBA The Mark H. Zangmeister Center - d/b/a The Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| Oklahoma University Medical Center | Oklahoma City | Oklahoma | 73104 | — |
| Penn State Univ. Milton S. Hershey Medical Center - MSHMC Cardiology | Hershey | Pennsylvania | 17033 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29245 | — |
| The West Clinic | Germantown | Tennessee | 38138 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| SCRI - Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology, P.A | Dallas | Texas | 75246 | — |
| Oncology Consultants, P.A. | Houston | Texas | 77030 | — |
| Texas Oncology, P.A. - Tyler | Tyler | Texas | 75702 | — |
| Northwest Medical Specialties, PLLC | Lakewood | Washington | 98499-3071 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01772004, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 20, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01772004 live on ClinicalTrials.gov.